DR. MIKEL DWAINE SMITH MD
Prescription History 1922012509
Internal Medicine - Cardiovascular Disease in Lexington, KY


Quality Rating: 100 out of 100 score

NPI Status: Active since July 28, 2006

Contact Information

GILL HEART INSTITUTE 800 ROSE ST
G100
LEXINGTON, KY
ZIP 40536
Phone: (859) 323-0295
Fax: (859) 257-8699

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. MIKEL DWAINE SMITH MD, an active Cardiovascular Disease specialist practicing in Lexington, KY. Our medical registry currently tracks 1 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 11 documented patient claims. Among these therapy options, the most frequently utilized medication is Warfarin Sodium, which accounts for 11 claims alone.

Medication Index

No matching medications currently found on file.

Warfarin Sodium

Generic Formulation: Warfarin SodiumSpecialty: Cardiology
Provider Metrics Summary
Total Claims 11
30-Day Fills 32.1
Days Supply 964
KY State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills88.4
Peer Average Days Supply2,535
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 77.1% less volume than the regional standard for practitioners inside KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $55.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$5.03

State Avg Cost Per Claim

$9.60

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.

Therapeutic Applications

This medication is used to treat blood clots (such as in deep vein thrombosis-DVT or pulmonary embolus-PE) and/or to prevent new clots from forming in your body. Preventing harmful blood clots helps to reduce the risk of a stroke or heart attack. Conditions that increase your risk of developing blood clots include a certain type of irregular heart rhythm (atrial fibrillation), heart valve replacement, recent heart attack, and certain surgeries (such as hip/knee replacement). Warfarin is commonly called a blood thinner, but the more correct term is anticoagulant. It helps to keep blood flowing smoothly in your body by decreasing the amount of certain substances (clotting proteins) in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. MIKEL DWAINE SMITH MD provides transparency into local medical care patterns within Lexington, KY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Cardiovascular Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.